Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients

References

• ZamboniWCStrychorSJosephEPlasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenograftsClin Cancer Res200713237217722318056203
   PubMed Web of Science ®Google Scholar
• ZamboniWCEisemanJLStrychorSTumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor modelsJ Liposome Res2011211708020528623
   PubMed Web of Science ®Google Scholar
• ZamboniWCLiposomal, nanoparticle, and conjugated formulations of anticancer agentsClin Cancer Res200511238230823416322279
   PubMed Web of Science ®Google Scholar
• CrulMCKD-602. Chong Kun DangCurr Opin Investig Drugs200341214551459
   Google Scholar
• LeeJHLeeJMLimKHPreclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivativeAnn N Y Acad Sci200092232432511193913
   PubMed Web of Science ®Google Scholar
• LeeDHKimSWSuhCBelotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II studyAnn Oncol200819112312717823384
   PubMed Web of Science ®Google Scholar
• YuNYConwayCPenaRLChenJYSTEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft modelsAnticancer Res2007274B2541254517695551
   PubMed Web of Science ®Google Scholar
• ZamboniWCFriedlandDMRamalingamSFinal results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumorsJ Clin Oncol (Meeting Abstracts)200624Suppl 18S2013
   Google Scholar
• SlatterJGSchaafLJSamsJPPharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patientsDrug Metab Dispos200028442343310725311
   PubMed Web of Science ®Google Scholar
• ZamboniWCStewartCFThompsonJRelationship between topotecan systemic exposure and tumor response in human neuroblastoma xenograftsJ Natl Cancer Inst19989075055119539245
   PubMedGoogle Scholar
• StewartCFZamboniWCCromWRTopoisomerase I interactive drugs in children with cancerInvest New Drugs199614137478880392
   PubMed Web of Science ®Google Scholar
• ZamboniWCConcept and clinical evaluation of carrier-mediated anticancer agentsOncologist200813324826018378535
   PubMed Web of Science ®Google Scholar
• InnocentiFKroetzDLSchuetzEComprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokineticsJ Clin Oncol200927162604261419349540
   PubMed Web of Science ®Google Scholar
• AllenTMHansenCPharmacokinetics of stealth versus conventional liposomes: effect of doseBiochim Biophys Acta1991106821331411911826
   PubMed Web of Science ®Google Scholar
• PapahadjopoulosDAllenTMGabizonASterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacyProc Natl Acad Sci U S A1991882411460114641763060
   PubMed Web of Science ®Google Scholar
• ZamboniWCMarucaLJStrychorSBidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumorsJ Liposome Res201121215816520626314
   PubMed Web of Science ®Google Scholar
• AllenTMCullisPRDrug delivery systems: entering the mainstreamScience200430356651818182215031496
   PubMed Web of Science ®Google Scholar
• KondoMOshitaFKatoYYamadaKNomuraINodaKEarly monocytopenia after chemotherapy as a risk factor for neutropeniaAm J Clin Oncol199922110310510025393
   PubMed Web of Science ®Google Scholar
• OshitaFYamadaKNomuraITanakaGIkeharaMNodaKProphylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancerAm J Clin Oncol200023327828210857893
   PubMed Web of Science ®Google Scholar
• FribergLEFreijsASandströmMKarlssonMOSemiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in ratsJ Pharmacol Exp Ther2000295273474011046112
   PubMed Web of Science ®Google Scholar
• FribergLEHenningssonAMaasHNguyenLKarlssonMOModel of chemotherapy-induced myelosuppression with parameter consistency across drugsJ Clin Oncol200220244713472112488418
   PubMed Web of Science ®Google Scholar
• MinamiHSasakiYSaijoNIndirect-response model for the time course of leukopenia with anticancer drugsClin Pharmacol Ther19986455115219834043
   PubMed Web of Science ®Google Scholar
• KrzyzanskiWJuskoWJMultiple-pool cell lifespan model of hematologic effects of anticancer agentsJ Pharmacokinet Pharmacodyn200229431133712518707
   PubMed Web of Science ®Google Scholar
• WooSKrzyzanskiWJuskoWJPharmacodynamic model for chemotherapy-induced anemia in ratsCancer Chemother Pharmacol200862112313317891399
   PubMed Web of Science ®Google Scholar
• KloftCWallinJHenningssonAChatelutEKarlssonMOPopulation pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugsClin Cancer Res200612185481549017000683
   PubMed Web of Science ®Google Scholar
• LégerFLoosWJBugatRMechanism-based models for topotecan-induced neutropeniaClin Pharmacol Ther200476656757815592328
   PubMed Web of Science ®Google Scholar
• LatzJEKarlssonMORusthovenJJGhoshAJohnsonRDA semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapyCancer Chemother Pharmacol200657441242616322990
   PubMed Web of Science ®Google Scholar
• FetterlyGJGraselaTHShermanJWPharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxelClin Cancer Res200814185856586318794097
   PubMed Web of Science ®Google Scholar
• van KesterenCZandvlietASKarlssonMOSemi-physiological model describing the hematological toxicity of the anti-cancer agent indisulamInvest New Drugs200523322523415868378
   PubMed Web of Science ®Google Scholar
• ZamboniWCRamalingamSFriedlandDMPhase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignanciesClin Cancer Res20091541466147219190127
   PubMed Web of Science ®Google Scholar
• ZamboniWCStrychorSMarucaLPharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignanciesClin Pharmacol Ther200986551952619675541
   PubMed Web of Science ®Google Scholar
• McKenzieSBClinical Laboratory Hematology2nd edUpper Saddle River, NJPrentice Hall2010
   Google Scholar
• BonatePLPharmacokinetic-Pharmacodynamic Modeling and Simulation1st edNew York, NYSpringer Science and Business Media Inc2005
   Google Scholar
• SheinerLBBealSLEvaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic dataJ Pharmacokinet Biopharm1980865535717229908
   PubMedGoogle Scholar
• SheinerLBRosenbergBMaratheVVEstimation of population characteristics of pharmacokinetic parameters from routine clinical dataJ Pharmacokinet Biopharm197755445479925881
   PubMedGoogle Scholar
• HilgerRARichlyHGrubertMPharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/DoxilInt J Clin Pharmacol Ther2005431258858916372528
   PubMedGoogle Scholar
• JainNCEssentials of Veterinary Hematology1st edHoboken, NJJohn Wiley and Sons1993
   Google Scholar
• WhitelawDMObservations on human monocyte kinetics after pulse labelingCell Tissue Kinet1972543113175044622
   PubMedGoogle Scholar
• KoningGAMorseltHWKampsJAScherphofGLUptake and intracellular processing of PEG-liposomes and PEG-immunoliposomes by kupffer cells in vitro 1*J Liposome Res2001112–319520919530933
   PubMed Web of Science ®Google Scholar
• Van RooijenNSandersAKupffer cell depletion by liposome-delivered drugs: comparative activity of intracellular clodronate, propamidine, and ethylenediaminetetraacetic acidHepatology1996235123912438621159
   PubMed Web of Science ®Google Scholar
• HaberEAferganEEpsteinHRoute of administration-dependent anti-inflammatory effect of liposomal alendronateJ Control Release2010148222623320813142
   PubMed Web of Science ®Google Scholar